Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's ...

Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe. The FDA has accepted two separate marketing applic ...

America faces a brewing public health threat as vaccination rates continue to slide downward. Diseases once eliminated ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

and rare diseases. It also develops and manufactures vaccines. Pfizer collaborated with German biotech company BioNTech SE (BNTX) to develop one of the world's most widely used mRNA-based vaccines ...

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share rose 17.0 ...

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Jenny Strasburg is a reporter in London, where she writes for The Wall Street Journal about oil and gas, climate, the ...